Corcept Therapeutics Incorporated

NasdaqCM:CORT Stock Report

Market Cap: US$2.6b

Corcept Therapeutics Past Earnings Performance

Past criteria checks 5/6

Corcept Therapeutics has been growing earnings at an average annual rate of 3.8%, while the Pharmaceuticals industry saw earnings growing at 1.7% annually. Revenues have been growing at an average rate of 10.7% per year. Corcept Therapeutics's return on equity is 20.9%, and it has net margins of 21.9%.

Key information

3.8%

Earnings growth rate

5.8%

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth rate10.7%
Return on equity20.9%
Net Margin21.9%
Last Earnings Update31 Dec 2023

Recent past performance updates

We Like Corcept Therapeutics' (NASDAQ:CORT) Earnings For More Than Just Statutory Profit

Feb 22
We Like Corcept Therapeutics' (NASDAQ:CORT) Earnings For More Than Just Statutory Profit

Recent updates

We Like Corcept Therapeutics' (NASDAQ:CORT) Earnings For More Than Just Statutory Profit

Feb 22
We Like Corcept Therapeutics' (NASDAQ:CORT) Earnings For More Than Just Statutory Profit

Corcept Therapeutics: Key Catalysts Ahead

Feb 19

After Leaping 29% Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Are Not Flying Under The Radar

Dec 23
After Leaping 29% Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Are Not Flying Under The Radar

Corcept Therapeutics Incorporated's (NASDAQ:CORT) Intrinsic Value Is Potentially 59% Above Its Share Price

Nov 07
Corcept Therapeutics Incorporated's (NASDAQ:CORT) Intrinsic Value Is Potentially 59% Above Its Share Price

Are Corcept Therapeutics Incorporated (NASDAQ:CORT) Investors Paying Above The Intrinsic Value?

Jun 23
Are Corcept Therapeutics Incorporated (NASDAQ:CORT) Investors Paying Above The Intrinsic Value?

Estimating The Intrinsic Value Of Corcept Therapeutics Incorporated (NASDAQ:CORT)

Feb 16
Estimating The Intrinsic Value Of Corcept Therapeutics Incorporated (NASDAQ:CORT)

Here's Why We Think Corcept Therapeutics (NASDAQ:CORT) Might Deserve Your Attention Today

Jan 11
Here's Why We Think Corcept Therapeutics (NASDAQ:CORT) Might Deserve Your Attention Today

Corcept Therapeutics starts phase 2 trial of its ALS treatment

Oct 11

Does Corcept Therapeutics (NASDAQ:CORT) Deserve A Spot On Your Watchlist?

Sep 27
Does Corcept Therapeutics (NASDAQ:CORT) Deserve A Spot On Your Watchlist?

Corcept extends distribution agreement for Cushing’s syndrome drug

Sep 23

Corcept Therapeutics: A Status Check

Sep 06

Corcept cut to Hold at Truist on balanced risk-reward setup

Aug 01

Corcept Therapeutics begins phase 3 trial of relacorilant for ovarian cancer

Jun 29

I Ran A Stock Scan For Earnings Growth And Corcept Therapeutics (NASDAQ:CORT) Passed With Ease

Jun 09
I Ran A Stock Scan For Earnings Growth And Corcept Therapeutics (NASDAQ:CORT) Passed With Ease

Is Now The Time To Put Corcept Therapeutics (NASDAQ:CORT) On Your Watchlist?

Feb 23
Is Now The Time To Put Corcept Therapeutics (NASDAQ:CORT) On Your Watchlist?

Revenue & Expenses Breakdown
Beta

How Corcept Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:CORT Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 23482105184184
30 Sep 2345091179166
30 Jun 2342894169154
31 Mar 2341494164144
31 Dec 22402101153131
30 Sep 22398117143123
30 Jun 22392113138118
31 Mar 22380112130113
31 Dec 21366113122114
30 Sep 21353106116114
30 Jun 2134398112119
31 Mar 2134099107118
31 Dec 20354106105115
30 Sep 20356109107111
30 Jun 20351114104100
31 Mar 2033510610495
31 Dec 193069410089
30 Sep 19285879583
30 Jun 19268789280
31 Mar 19258768778
31 Dec 18251758175
30 Sep 182381527770
30 Jun 182161487263
31 Mar 181891426650
31 Dec 171591296240
30 Sep 17130355733
30 Jun 17109245229
31 Mar 1793135026
31 Dec 168184524
30 Sep 167254221
30 Jun 166414118
31 Mar 1656-23816
31 Dec 1550-63715
30 Sep 1544-113615
30 Jun 1538-173615
31 Mar 1532-223515
31 Dec 1427-313518
30 Sep 1422-393421
30 Jun 1417-443223
31 Mar 1413-483323
31 Dec 1310-463120
30 Sep 138-463019
30 Jun 136-432917
31 Mar 135-392615

Quality Earnings: CORT has high quality earnings.

Growing Profit Margin: CORT's current net profit margins (21.9%) are lower than last year (25.2%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: CORT's earnings have grown by 3.8% per year over the past 5 years.

Accelerating Growth: CORT's earnings growth over the past year (4.2%) exceeds its 5-year average (3.8% per year).

Earnings vs Industry: CORT earnings growth over the past year (4.2%) exceeded the Pharmaceuticals industry -0.5%.


Return on Equity

High ROE: CORT's Return on Equity (20.9%) is considered high.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.